KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Total Current Liabilities: 2010-2024

Historic Total Current Liabilities for Nektar Therapeutics (NKTR) over the last 15 years, with Dec 2024 value amounting to $61.4 million.

  • Nektar Therapeutics' Total Current Liabilities fell 1.84% to $66.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $66.3 million, marking a year-over-year decrease of 1.84%. This contributed to the annual value of $61.4 million for FY2024, which is 19.76% up from last year.
  • According to the latest figures from FY2024, Nektar Therapeutics' Total Current Liabilities is $61.4 million, which was up 19.76% from $51.3 million recorded in FY2023.
  • Nektar Therapeutics' Total Current Liabilities' 5-year high stood at $115.8 million during FY2020, with a 5-year trough of $51.3 million in FY2023.
  • Over the past 3 years, Nektar Therapeutics' median Total Current Liabilities value was $61.4 million (recorded in 2024), while the average stood at $60.3 million.
  • In the last 5 years, Nektar Therapeutics' Total Current Liabilities crashed by 67.28% in 2020 and then rose by 19.76% in 2024.
  • Over the past 5 years, Nektar Therapeutics' Total Current Liabilities (Yearly) stood at $115.8 million in 2020, then declined by 26.41% to $85.2 million in 2021, then decreased by 19.95% to $68.2 million in 2022, then fell by 24.83% to $51.3 million in 2023, then climbed by 19.76% to $61.4 million in 2024.